Taikang Asset Management Hong Kong Co Ltd Sells 8,542 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Taikang Asset Management Hong Kong Co Ltd reduced its position in IQVIA Holdings Inc. (NYSE:IQV) by 24.1% in the 4th quarter, Holdings Channel reports. The firm owned 26,944 shares of the medical research company’s stock after selling 8,542 shares during the quarter. Taikang Asset Management Hong Kong Co Ltd’s holdings in IQVIA were worth $5,295,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Avior Wealth Management LLC boosted its position in shares of IQVIA by 117.6% during the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after acquiring an additional 87 shares in the last quarter. Synergy Asset Management LLC acquired a new stake in IQVIA during the fourth quarter valued at approximately $33,000. Lee Danner & Bass Inc. bought a new stake in shares of IQVIA in the 4th quarter valued at approximately $44,000. Versant Capital Management Inc raised its holdings in shares of IQVIA by 46.0% in the 4th quarter. Versant Capital Management Inc now owns 295 shares of the medical research company’s stock worth $58,000 after buying an additional 93 shares in the last quarter. Finally, SBI Securities Co. Ltd. acquired a new stake in IQVIA in the 4th quarter valued at $60,000. Institutional investors own 89.62% of the company’s stock.

Wall Street Analyst Weigh In

IQV has been the subject of a number of analyst reports. Royal Bank of Canada reissued an “outperform” rating and set a $270.00 price objective on shares of IQVIA in a report on Monday, February 10th. Barclays reduced their price target on shares of IQVIA from $255.00 to $235.00 and set an “overweight” rating on the stock in a research report on Monday, February 3rd. Stephens initiated coverage on shares of IQVIA in a report on Friday, December 20th. They set an “overweight” rating and a $250.00 price objective for the company. JPMorgan Chase & Co. decreased their price target on IQVIA from $240.00 to $232.00 and set an “overweight” rating on the stock in a research report on Tuesday, February 18th. Finally, BTIG Research downgraded IQVIA from a “buy” rating to a “neutral” rating in a research report on Monday, February 3rd. Five equities research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $249.05.

IQVIA Stock Up 0.2 %

IQVIA stock opened at $186.35 on Tuesday. IQVIA Holdings Inc. has a fifty-two week low of $179.28 and a fifty-two week high of $254.54. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The firm has a market capitalization of $32.86 billion, a price-to-earnings ratio of 24.85, a PEG ratio of 1.99 and a beta of 1.50. The company’s 50 day simple moving average is $194.58 and its 200 day simple moving average is $207.73.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.